NASDAQ: ICCMIcecure Medical Ltd Stock
$0.90+0.06 (+7.14%)
Updated Aug 15, 2025
ICCM Price
$0.90
Fair Value Price
-$0.30
Market Cap
$52.64M
52 Week Low
$0.48
52 Week High
$1.66
P/E
-3.21x
P/B
18.21x
P/S
20.96x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.79M
Earnings
-$15.58M
Gross Margin
35.9%
Operating Margin
-569.07%
Profit Margin
-559%
Debt to Equity
2.66
Operating Cash Flow
-$14M
Beta
0.71
Next Earnings
Aug 18, 2025
Ex-Dividend
N/A
Next Dividend
N/A
ICCM Overview
IceCure Medical Ltd. develops medical devices to cryoablate (freeze) tumors in the human body. It offers the ProSense system, a cryoablation solution for the treatment of breast tumors. Icecure Medical supports investigator-initiated studies at various academic institutions. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ICCM's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important ICCM news, forecast changes, insider trades & much more!
ICCM News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ICCM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ICCM ($0.90) is overvalued by 395.09% relative to our estimate of its Fair Value price of -$0.30 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ICCM ($0.90) is not significantly undervalued (395.09%) relative to our estimate of its Fair Value price of -$0.30 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ICCM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ICCM due diligence checks available for Premium users.
Valuation
ICCM fair value
Fair Value of ICCM stock based on Discounted Cash Flow (DCF)
Price
$0.90
Fair Value
-$0.30
Undervalued by
395.75%
ICCM ($0.90) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ICCM ($0.90) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ICCM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ICCM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.21x
Industry
31.63x
Market
35.99x
ICCM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
18.21x
Industry
4.01x
ICCM is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ICCM's financial health
Profit margin
Revenue
$525.0k
Net Income
-$3.4M
Profit Margin
-640.8%
ICCM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ICCM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$10.6M
Liabilities
$7.7M
Debt to equity
2.66
ICCM's short-term assets ($9.02M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ICCM's short-term assets ($9.02M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ICCM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.8M
Investing
-$23.0k
Financing
$2.1M
ICCM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ICCM vs Medical Device Stocks
Icecure Medical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.